PHARMAC - Latest News [Page 1]

Multiple Funding Proposals Being Considered By Pharmac

Thursday, 19 May 2022, 4:47 pm | PHARMAC

Pharmac has issued three consultations today on proposals to fund medicines for conditions including cancer, multiple sclerosis, hormone replacement and HIV. The treatments being considered are estimated to benefit thousands of New Zealanders ... More >>

Pharmac Will Use Biggest Budget Increase Ever To Fund More Medicines For More New Zealanders

Thursday, 19 May 2022, 2:25 pm | PHARMAC

Pharmac welcomes the $191 million increase to its pharmaceutical budget over the next two years. It is already working its way through the medicines options for investment (OFI) list, looking at what agreements it can now make with pharmaceutical suppliers. ... More >>

Pharmac Widens Access To Medicine For RSV

Monday, 16 May 2022, 10:16 am | PHARMAC

Pharmac has announced today that it will be funding the preventative treatment, palivizumab, for the next two seasons of respiratory syncytial virus (RSV) for young children with severe diseases who need to be ventilated and pēpi (babies) with a ... More >>

Access Criteria For Antiviral Treatments Widened As Molnupiravir Arrives In New Zealand

Thursday, 28 April 2022, 2:15 pm | PHARMAC

Pharmac is widening access to the antivirals to treat people with early COVID-19, after receiving feedback from our expert advisors and clinicians that the access criteria needed updating and to be streamlined. This comes in time for the arrival ... More >>

Pharmac Welcomes Analysis Into Cancer Medicines In Aotearoa

Thursday, 28 April 2022, 5:46 am | PHARMAC

Pharmac welcomes a new report released today by Te Aho o Te Kahu (the Cancer Control Agency) which analyses the access and efficacy of cancer medicines for solid tumours in adult patients in Aotearoa. The new analysis, Understanding the gap: an analysis ... More >>

8,700 More Pacific Peoples Need Treatment To Prevent Gout Each Year To Achieve Equity

Monday, 11 April 2022, 1:14 pm | PHARMAC

Pharmac has released the Pacific peoples health – Gout data insights report today. The report shows that, while the prevalence of gout in Pacific peoples continues to climb, access to preventive gout medicine remains inequitable. The latest insights ... More >>

Pfizer’s Oral COVID-19 Treatment Arrives In New Zealand

Thursday, 31 March 2022, 6:55 am | PHARMAC

The first shipment of Pfizer’s new oral antiviral treatment for COVID-19, Paxlovid, has arrived in New Zealand and will be available for those who need it from next week. “While vaccinations and booster shots are the best defence against COVID-19, ... More >>

Pharmac To Fund New Treatments For Lung And Ovarian Cancer

Wednesday, 16 March 2022, 12:03 pm | PHARMAC

Pharmac has confirmed today they are funding a bundle deal which will give New Zealanders more effective treatment options for lung cancer and ovarian cancer. The bundle deal also includes a new medicine for people with severe eosinophilic asthma. The bundle ... More >>

Pūahoaho: Clarity Around Pharmac’s Priority Lists

Wednesday, 9 March 2022, 9:02 am | PHARMAC

Pharmac has released up-to-date information about its priority lists, including a list of declined medicine applications as part of its ongoing commitment to transparency. “We want New Zealanders to know we have heard their concerns about a lack of transparency. ... More >>

Pharmac Proposes Widened Access To The Flu Vaccine For Māori And Pacific Peoples For 2022 Season

Tuesday, 8 March 2022, 11:22 am | PHARMAC

Pharmac is consulting on a proposal to widen access to the funded influenza vaccine to include Māori and Pacific peoples aged between 55 and 64 years of age for the 2022 influenza season. Read the consultation on widening access “We anticipate ... More >>

Pharmac Updates Access Criteria For Remdesivir

Friday, 4 March 2022, 1:56 pm | PHARMAC

Pharmac has heard from our expert advisors and clinicians treating people with COVID-19 that we need to make further changes to the temporary access criteria for remdesivir. “On Monday 28 February Pharmac temporarily widened access criteria to remdesivir ... More >>

Flu Vaccine Price Increase

Tuesday, 1 March 2022, 9:45 am | PHARMAC

Pharmac has confirmed that the purchase price of the annual influenza vaccine will increase by $2 a dose, the first increase since 2008. “The influenza vaccine has been supplied at $9 a dose for the last 14 years,” says Pharmac’s Director of ... More >>

Pharmac Ensures Earlier Access To Key COVID-19 Treatment

Monday, 28 February 2022, 2:29 pm | PHARMAC

The access criteria for remdesivir is being temporarily widened to allow hospitals to treat those with mild to moderate symptoms of COVID-19, who are at high risk of severe disease, as of today. “We initially purchased remdesivir to treat people ... More >>

Pharmac Publishes Experts’ Advice And Seeks Views On Access Criteria For COVID-19 Treatments

Wednesday, 16 February 2022, 2:41 pm | PHARMAC

Pharmac is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient access criteria for two COVID-19 antiviral treatments – molnupiravir (branded as Lagevrio) and nirmatrelvir with ritonavir (Paxlovid). ... More >>

Pharmac Proposing To Widen Access To Funded Medicines

Monday, 14 February 2022, 10:05 am | PHARMAC

Pharmac has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic acid, estimated to benefit 1,750 New Zealanders a year. “Rituximab is a monoclonal antibody medicine, administered as an intravenous infusion,” ... More >>

PHARMAC Confirms Access Criteria For COVID-19 Treatments

Wednesday, 26 January 2022, 3:13 pm | PHARMAC

Pharmac has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with imdevimab (branded as Ronapreve). Both will be available for use in DHB hospitals from 1 February 2022. “Pharmac uses access criteria to ... More >>

Pharmac Publishes Experts’ Advice And Seeks Views On Patient Access Criteria For COVID-19 Treatments

Wednesday, 22 December 2021, 2:29 pm | PHARMAC

Pharmac is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback on the patient access criteria for two funded COVID-19 treatments – baricitinib and casirivimab and imdevimab (branded as Ronapreve). ... More >>

Pharmac’s Year In Review

Monday, 20 December 2021, 11:07 am | PHARMAC

Today Pharmac has released its Year in Review for 2021, an annual publication highlighting key aspects of the agency’s work throughout the year. “We know New Zealanders want to learn more about our work and how we make funding decisions. We are working ... More >>

Pharmac Looking To Fund Medicines For Lung And Ovarian Cancer

Thursday, 16 December 2021, 10:54 am | PHARMAC

Pharmac is considering funding a bundle deal which would give New Zealanders more effective treatment options for lung cancer and ovarian cancer. The bundle deal also includes a new medicine for people with severe eosinophilic asthma. The bundle deal ... More >>

New Report Estimates 10,400 More Māori Should Be On Preventive Treatment For Gout

Wednesday, 8 December 2021, 12:43 pm | PHARMAC

Pharmac has today released the first of a series of reports investigating inequities in medicine access. The report looks specifically at prescribing and dispensing medicines for gout, estimating 10,400 more Māori need preventive treatment each year to achieve ... More >>

 

 
 
 
 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL